Study details
Enrolling now
CLEAR HIV Trial
Priscilla Hsue, MD
NCT IDNCT05488431ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
121
Study length
about 5 years
Ages
40+
Locations
3 sites in CA, TX
About this study
Researchers are testing whether Bempedoic acid, a medication, can lower cholesterol and inflammation in people with HIV who have heart disease or risk factors for it. The trial will last 1827 days and involve approximately 121 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Bempedoic acid
PhasePhase 2
DrugBempedoic acid
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
bempedoic acid
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Hb A1c Endpoint, IL-6 Endpoint, Triglycerides Endpoint
Body systems
Cardiology / Heart, Immune, Infectious